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Introduction: The impact of treatment delays on survival of
patients with non-small cell lung cancer (NSCLC) is uncertain.
Although later treatment could negatively affect psychological
well-being, the maximum acceptable waiting time has not been
determined.
Methods: We analyzed consecutive patients with NSCLC between
January 2005 and May 2007 in our center. Treatment delay was
calculated from the first abnormal radiographic study. Cox propor-
tional hazards analysis was used to identify predictive factors and
log-rank tests to compare survival.
Results: Four hundred ninety-five cases were identified; shorter
treatment delays were associated with a poor prognosis. Conversely,
for every week that the treatment could be delayed, the hazard ratio
was improved at 0.97 (p  0.05). Standard treatment was given to
319 of these patients who were separated in localized, regional, and
advanced stages. The median treatment delay was 73 days and
distributed as follows: 85, 94, and 50 days for localized, regional,
and advanced stages, respectively (p  0.01). For localized or
regional stages, the association between treatment delay and survival
was inconclusive. In the advanced group, each week of treatment
delay had a hazard ratio of 0.93 (p  0.009). Survival of advanced
patients who began treatment earlier versus later than the group
median was 6.8 versus 11.6 months (p  0.027).
Conclusions: For patients with advanced NSCLC receiving equiv-
alent chemotherapy regimens, shorter treatment delays were associ-
ated with shorter survival. We hypothesize that urgent treatment
carried a negative prognostic meaning, as this was preferentially
offered to patients presenting with a higher symptom burden, which
conferred them a worse outcome.
Key Words: Non-small cell, Treatment delays, Survival, Standard
treatment.
(J Thorac Oncol. 2011;6: 1254–1259)
Lung cancer is the leading cause of cancer-related deaththroughout the world affecting especially industrialized
countries.1 Most patients present with advanced-stage disease
for which the treatment remains palliative.2 Quebec is one of
Canada’s most affected provinces, with mortality rates sim-
ilar to those of the five next common cancers combined
(colon, breast, pancreas, prostate, and lymphoma).3
The diagnostic workup is often a lengthy process,
involving a complex algorithm and serial procedures (bron-
chial or percutaneous biopsy, mediastinal lymph node sam-
pling, and evaluation for distant metastases), as described in
the American College of Chest Physicians 2nd edition guide-
lines.4 Canada’s healthcare system is publicly funded and can
occasionally become encumbered by a rising patient burden.5
These required sequential investigations in non-small cell
lung cancer (NSCLC) generate concerns for increased wait-
ing time to access consultative, diagnostic, and treatment
services.
A number of prognostic factors have been described in
NSCLC. The most reproducible ones include stage of disease,
performance status (PS), and weight loss6,7; there is consid-
erable interest lately in molecular biomarkers such as epider-
mal growth factor receptor and k-ras mutations, among oth-
ers.8,9 It is still uncertain whether increases in the treatment
delays are associated with stage progression or otherwise
compromised patient outcome. This study is a retrospective
analysis of patients with NSCLC treated at our institution
evaluating several prognostic factors, including treatment
delays.
PATIENTS AND METHODS
Hoˆpital du Sacre´-Coeur de Montre´al, Canada, is a 600
in-bed teaching hospital, serving the northern Montreal met-
ropolitan area. Thoracic surgery and chemotherapy are avail-
able on site, and positron emission tomography, transesoph-
ageal biopsy, and radiotherapy are available off site on a
priority consultation service.
Patients with a histological diagnosis of NSCLC in our
center between January 2005 and May 2007 were entered into
this study. Data were collected from our local tumor registry,
a retrospective database built following the standards set forth
by the American College of Surgeons. New cases of NSCLC
were identified as follows: a computer search of hospital
discharge diagnoses was run through the hospital’s electronic
database; in addition, a comprehensive manual search of all
pathology reports and outpatient pulmonology and oncology
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clinics was performed. Information was also complemented
from the radiology database and from patient chart review.
Staging was done using the sixth tumor, node, metastasis
(TNM) classification,10 and pathological staging, when avail-
able, was prioritized over clinical staging. Treatment delays
were calculated from the date of the first abnormal radiology
study that was suspicious for lung cancer, and survival was
calculated from the start of treatment. The institutional re-
search ethics board approved this study.
Statistical analyses were done using the SPSS 17.0
software. Simple statistics included the 2 test to compare
proportions and the Mann-Whitney U test to compare treat-
ment delays as they displayed a non-normal distribution
curve. Survival curves were generated using the Kaplan-
Meier method, and the log-rank test was used for comparison.
Both univariate and multivariate Cox regression models were
used to explore the association between survival and different
patient characteristics.
Patients received a wide array of treatments, according
to their disease stage, comorbidities, and/or PS. The treatment
approaches were categorized as standard, if they were con-
sidered to be appropriate for the patient’s stage: surgery for
stages I and II / adjuvant chemotherapy, multimodality
treatment for stage III, and platinum-based chemotherapy for
stage IV. Alternative antineoplastic treatments, given to pa-
tients with altered PS or limited cardio-respiratory function,
were categorized as nonstandard (i.e., radiotherapy for local-
ized disease, single modality treatment for regional disease,
or antineoplastic treatment other than platinum-based chemo-
therapy for advanced disease); finally, hospice care consisted
of symptom management alone.
RESULTS
Diagnostic Cohort
Six hundred sixty-five patients received a diagnosis of
primary lung cancer during the study period. In 56 of them,
no histopathology was available, 3 patients were diagnosed
with carcinoid cancer, and 1 had sarcomatoid carcinoma. In
the remaining 605 patients, 89 (15%) had small-cell histology
and 516 (85%) had NSCLC. Most patients presented with
advanced stages at diagnosis, as 60% were III-B or IV.
Out of this diagnostic cohort, 21 patients did not return
for medical care to our hospital and the remaining 495
patients were retained for outcome analyses. The types of
treatment received were categorized as follows: standard
treatment for 319 (64%) patients, nonstandard treatment for
92 (19%) patients, and hospice care for 84 (17%) patients.
When analyzed by disease stage, a lower proportion of
patients could receive a standard treatment as stage increased;
84% of stages I and II, 67% of stage III, and 46% of stage IV
patients (Figure 1).
Treatment delay data were available in 85% of patients
referred for hospice care (time from abnormal image to
hospice care decision), 98% of patients receiving a nonstan-
dard treatment, and 100% of patients receiving a standard
treatment. The median treatment delay of the whole group
was 62 days (25–75% interquartile range [IQR]  30–108
days). The shortest delays were for hospice care (29 days)
and the longest were for starting a standard treatment (73
days), p  0.022 (Table 1).
Several factors were analyzed in a Cox proportional
hazards model for survival (n  495 patients): age, gender,
smoking history, histology (squamous versus other), type of
treatment (hospice versus nonstandard versus standard), dis-
ease stage, and treatment delays. These variables were se-
lected as generally recognized to have prognostic value6,7 or
interesting to study (treatment delays). Other factors were not
entered in the analysis because of lack of sufficient data: race,
weight loss, PS, and oncogenic mutations. Type of treatment,
disease stage, and treatment delays were significantly asso-
ciated with overall survival, both in uni- and multivariate
analyses (Table 2). Nonstandard treatment and hospice care
were poor and very poor prognostic factors, respectively,
compared with standard treatment. Advanced stage of disease
was also confirmed as a poor prognostic factor. Finally,
treatment delays were significantly associated with survival
(p  0.005); for every week that the treatment could be
delayed, the multivariate hazard ratio (HR) was 0.97 (95%
confidence interval [CI]  0.96–0.99). For every month of
treatment delay, survival was proportionally improved with a
HR of 0.89 (95% CI 0.82–0.97). We sought to analyze this
association in more detail within the standard treatment
group.
FIGURE 1. Distribution of treatment groups according to
disease stages (n  495). Standard indicates recommended
treatments for the respective disease stage; nonstandard in-
dicates alternative antineoplastic treatments; and hospice
indicates symptom management alone.
TABLE 1. Treatment Delays According to Treatment Group
Approach Median (d) 25–75% IQR
Hospice care (n  71) 29 16–57
Nonstandard treatment (n  90) 51 21–110
Standard treatment (n  319) 73 42–110
All (n  480) 62 30–108
IQR, interquartile range; n, patients with available data.
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Standard Treatment Cohort
The characteristics of the 319 patients who received a
standard treatment are listed in Table 3. They were separated
into three groups according to their TNM staging and the
intended treatment: localized (n  127), regional (n  68),
and advanced (n 124). Their treatments are described in the
following section.
Patients with localized disease included stages I and II
and were treated with surgery. Lobectomy was the most
common procedure (n  103), followed by sublobar resec-
tion (n  18) and pneumonectomy (n  6). Among the
patients with stages IB and II, 20% received adjuvant che-
motherapy.
The cohort with regional disease included most of stage
III (36 and 32 patients in stages IIIA and IIIB, respectively)
and was treated with a combined approach. Surgery was
performed in 31 patients, and 50% received either pre- or
postoperative chemotherapy. In the remaining 37 patients, a
chemoradiation approach was used, either concomitantly in
75% or sequentially in 25% of them. Twelve percent of the
regional group patients were presented at multidisciplinary
tumor board discussions.
The cohort with advanced disease included patients
with stages IIIB (n 26) not eligible for radical radiotherapy
and stage IV (n  98). Out of the stage IV patients, 27% had
brain metastasis at diagnosis. Chemotherapy consisted of a
platinum-based doublet; carboplatin was used in 114 (92%)
regimens, combined with gemcitabine (n  95), vinorelbine
(n  11), taxol (n  7), or etoposide (n  1), and cisplatin 
vinorelbine was given to the remaining 10 (8%) patients.
Forty percent of patients received radiotherapy before starting
chemotherapy. The median number of chemotherapy cycles
was 4 (range 1–6). Thirteen percent of patients were enrolled
in research protocols with investigational agents, and they
were analyzed within this group.
Second-line chemotherapy was administered to 57
(47%) patients in the advanced group and to 13 patients who
relapsed from the local and regional groups after their pri-
mary treatment. The most frequently used second-line regi-
men was taxotere in 60% of cases, followed by tyrosine
kinase inhibitors and pemetrexed. Out of the 70 patients
receiving second-line, 35 (50%) received a third-line treat-
ment. The most frequently used drug in the third-line treat-
ment was erlotinib in 60% of cases, followed by taxotere and
pemetrexed. Fourth-line treatment was subsequently given to
eight of these patients.
We compared the treatment delays for the three groups
of patients: localized, regional, and advanced (Table 4). This
represented time from abnormal radiology to either surgery—
for localized, multimodality—for regional, and chemother-
apy—for advanced patients. The advanced group had the
shortest treatment delay of 50 days when compared with the
localized and regional groups who had a median treatment
delay of around 3 months (p  0.001).
Outcomes of the Standard Treatment Cohort
With a median follow-up of 8 months, 193 (61%) of the
patients were still alive. Overall survival separated by the
three-stage groups is shown in Figure 2. Median survival
times estimated by the Kaplan-Meier method were 35 months
for localized, 30 months for regional, and 8 months for the
advanced group (p  0.001).
Several factors were analyzed for their prognostic as-
sociation with survival. Given the fact that there were rela-
tively few events (deaths) within the localized and regional
groups (19 and 20 deaths, respectively), they were combined
together for the proportional hazards analysis. There were 87
deaths in the advanced group, which was analyzed separately.
TABLE 4. Treatment Delays According to Disease Extent
(n  319)
Stages Median (d) 25–75% IQR
Localized (n  127) 85 58–130
Regional (n  68) 94 60–121
Advanced (n  124) 50 30–76
IQR, interquartile range.
TABLE 2. Uni- and Multivariate Analyses for Survival for the
three Treatment Cohorts (n  495)
Variables
Univariate Multivariate
p HR p HR
Types of treatment 0.001 0.001
Standard Reference Reference
Nonstandard 2.04 1.60
Hospice care 5.56 7.26
Stages 0.001 0.001
I and II Reference Reference
III 2.33 2.14
IV 5.65 5.87
Treatment delays 0.001 0.005
1 wk 0.95 0.97
1 mo 0.81 0.89
Other factors used in the analysis were age, gender, smoking history, and histology.
HR, hazard ratio.
TABLE 3. Characteristics of Patients Receiving Standard
Treatment
Characteristics n  319
Age (yr), median (range) 62 (26–82)
Gender
Men 55%
Women 45%
Histology
Squamous 23%
Other NSCLC 77%
Smoking
Yes 88%
No 3%
Unknown 9%
Pack-years, median (range) 42 (5–125)
NSCLC, non-small cell lung cancer.
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Common factors, used in all the analyses, were age, gender,
smoking status, histology, and treatment delays, which were
considered as a continuous variable. Factors specific for the
local-regional group were disease stage (local versus regional
and pathological versus clinical) and tumor board presenta-
tion. Factors specific for the advanced group were disease
stage (IIIB versus IV), prior radiation therapy, brain metas-
tasis, and research protocol enrolment.
For the local-regional group (n  195), the only sig-
nificant factor associated with survival was age; in univariate
analysis, the HR was 1.05 (95% CI  1.01–1.09, p  0.015).
In the multivariate analysis, the HR was 1.06 (95% CI 
1.01–1.10, p  0.01). None of the other factors analyzed,
including treatment delays, were associated with survival.
For the advanced group (n  124), the only significant
factor associated with survival was treatment delay. The
univariate HR was 0.94 (95% CI  0.91–0.98) for every
week that the treatment could be delayed and 0.78 (95% CI
0.65–0.93) for every month of delay (p  0.006). In multi-
variate analyses, for every week of delay, the HR for survival
was 0.93 (0.88–0.98). Proportionally, every month of treat-
ment delay was associated with an improved survival by a
HR of 0.74 (0.59–0.93), p  0.009. Figure 3 shows overall
survival of advanced patients according to the treatment delay
compared with the median wait time, which was 50 days. The
median survival of patients who were treated on a more
urgent basis (wait time lower than median) was 6.8 months,
when compared with 11.6 months for patients with treatment
delays beyond the median, p  0.027.
DISCUSSION
One of the most important prognostic factors in
NSCLC is the TNM stage. Unfortunately, the majority of
patients present with an advanced stage at diagnosis, contrib-
uting to their relatively limited overall survival. In this anal-
ysis, we sought to describe our local experience with the
epidemiology and outcome of the disease and look for prog-
nostic factors.
The traditional model of NSCLC natural history has
been challenged recently. The theory of local growth and
progression toward loco-regional invasion and distant metas-
tasis predicts that an earlier diagnosis and treatment should
improve survival. Results from screening studies so far have
not convincingly proven this concept and it is possible that
asymptomatic nodules discovered through screening have a
different natural history and perhaps do not represent precur-
sors of advanced cancer.11 Furthermore, data from the Inter-
national Adjuvant Lung Cancer Trial12 and its recent update13
show that approximately 60% of patients operated for early-
stage disease eventually developed local or distant recur-
rence, suggesting that micrometastases could occur much
earlier than they become clinically apparent in unscreened
patients.
Canada’s healthcare system faces, among other con-
straints, an increase in the incidence of patients with cancer.
In this context, an analysis of delays in receiving standard
treatment and their association with survival in NSCLC
becomes interesting, and, to our knowledge, this is one of the
first studies in this particular setting.
Treatment delays in our center could be either system
related, because of delays in diagnostic or treatment proce-
dures, or patient related, because of their noncompliance, and
no distinction could be made between the two. System-
related delays between the first abnormal radiology study and
treatment initiation were multifactorial (data not shown); they
included waiting times for physician appointments (pul-
monologist, thoracic surgeon, cardiologist, radiation, and/or
medical oncologist), diagnostic tests or procedures (com-
puted tomography, positron emission tomography, bronchos-
copy, mediastinoscopy, endoscopic ultrasound, pathological
examination, and cardiac and pulmonary function testing),
and treatment planning and initiation.
Other studies have found similar trends; a report from
Sweden14 using data from the regional cancer registry re-
ported a median symptom to treatment delay in NSCLC of
4.6 months. Patients with advanced stages of disease had the
FIGURE 2. Survival of 319 patients receiving
standard treatment according to stage.
FIGURE 3. Overall survival of patients with advanced dis-
ease according to length of delay (n  124). OS, overall sur-
vival; Tx, treatment.
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shortest treatment delay. In the multivariate analysis, shorter
treatment delays were associated with poor survival even
after correcting for disease stage, and the highest impact was
found within the advanced stages. In another study from
Finland,15 a similar pattern of worse outcome with short
treatment delay was seen in advanced stages of disease but
not in those with limited disease. The median treatment delay
in this study was 112 days, and it was shorter for patients with
advanced disease.
Two other studies reported on treatment delays in lung
cancer, and their global results (all stages and treatment
approaches combined) were the following: one report from
France16 found a median of 62 days starting from the first
symptom and another study, from Ireland,17 reported 54 days
from general practitioner referral to treatment. There are
several differences with our study, like the probable inclusion
of small-cell histology and/or different definitions of the
diagnosis date; however, globally, these waiting times seem
comparable with those presented in this study. In some of the
above-mentioned articles, treatments were grouped into sur-
gical, nonsurgical, and supportive.
In our study, we were able to show that, even when the
treatments were categorized according to the recommended
approach for the stage, these findings still held for advanced
patients. We separated out the patients who were not able to
tolerate standard chemotherapy and whose median survival
was shorter; the subset of stage IV patients receiving hospice
care or nonstandard antineoplastic treatment survived for a
median of only 16 and 109 days, respectively. The standard
treatment cohort received platinum-based chemotherapy
within the same center; in this more homogenous group, the
treatment delay was significantly associated with survival in
multivariate analysis; for every week that the treatment could
be delayed, survival was better by 7%. When the same group
was separated according to the median delay, the overall
survival was almost double for patients who could initiate
treatment later versus those who needed to be treated earlier
than 50 days (11.6 versus 6.8 months).
The reasons why the “early” treatment group had a
shorter survival are unclear. Adverse prognostic factors pres-
ent in this group might have been: worse PS, weight loss,
comorbidities, and/or molecular biomarkers, which were not
available for analysis. Another possibility is that patients
having more symptoms came to medical attention and were
referred for workup and treatment sooner than those having
less or no symptoms. Although these data are not available,
the “early” treatment group might have included more symp-
tomatic patients than the “delayed” group, which conferred
them a worse prognosis. This would corroborate with reports
suggesting that symptom burden is a negative prognostic
factor18 and that their improvement with treatment correlates
with better survival.19
One of the limitations of this study is its retrospective
nature, which lead to some missing data, as mentioned (PS,
weight loss, and comorbidities). These variables are not
routinely documented in cancer registries according to cur-
rent standards and have proven difficult to extract from
medical charts of unselected patients. Nevertheless, a pro-
spective randomized trial on treatment delay would be clin-
ically and ethically unacceptable. A hospital-based registry
could, on the other hand, be modified to prospectively collect
information on such variables and facilitate further studies,
provided appropriate measures are taken to improve their
recording in the medical chart.
We could not find any indication that our waiting times
adversely impacted outcome because of disease progression.
Waiting times were longer in localized and regional stages
than in advanced disease (85, 94, and 50 days, respectively),
leaving no indirect evidence of stage progression during the
wait time. These differences are probably a reflection of the
longer waiting times to adequately diagnose and treat local-
ized and regional disease compared with advanced disease.
Indeed, in our experience, it took fewer diagnostic steps to
complete the staging and comorbidity evaluations of ad-
vanced patients, compared with the loco-regional ones.
In addition, there was no indirect evidence of patients’
general status deterioration during the waiting time. Patients
referred for hospice care, mostly for decreased PS, had the
shortest waiting time followed by patients referred for non-
standard antineoplastic treatments (29 and 51 days, respec-
tively). The longest waiting times were experienced by pa-
tients treated with standard approaches (73 days) who also
represented the majority of the group (64%).
With regards to localized and regional patients, no
conclusive association could be found between treatment
delays and overall survival. These findings are similar to
those from a study done in the United States,20 which in-
cluded patients with stages I to III NSCLC being treated in
both public and private hospitals and reported image-to-
treatment intervals. Patients in the public system had a sig-
nificantly longer treatment delay than those from the private
hospitals (76 versus 45 days, respectively). Nevertheless, no
association could be found between waiting time and sur-
vival, despite comprehensive data analysis.
For the local and regional stages, we further analyzed
the 3-month treatment delay, with regards to the timing of the
pathological diagnosis of NSCLC. In 105 patients, repeated
attempts at tissue sampling were nondiagnostic before the
therapeutic surgical resection. Their diagnostic and treatment
delays were therefore the same, at 88 days (25–75% IQR 
58–130 days). For the remaining 90 patients, pathological
diagnosis was successful before definitive treatment, through
bronchoscopy, mediastinoscopy, percutaneous, or trans-
esophageal biopsy. Their median delays between radiological
and pathological diagnosis were 31 days (25–75% IQR 
13–57 days). Thereafter, their median delays between path-
ological diagnosis and treatment were 56 (25–75% IQR 
43–70) days for the localized patients (treated by surgery) and
61 (25–75% IQR  37–88) days for the regional patients
(treated by chemoradiotherapy). All these intervals included
also delays for physician appointments and imaging studies.
These intervals should be compared with the tumor
doubling time in NSCLC, which was estimated to be around
3 months for squamous cell tumors and around 6 months for
adenocarcinomas.21 It is therefore suspected that our median
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of approximately 2 months of treatment delay did not signif-
icantly impact survival in our cohort.
Finally, treatment delays are very likely to have a
negative impact on patients’ psychological well-being and
indirectly on their quality of life, parameters not available for
our analysis. Multidisciplinary tumor board presentations
have greatly increased since 2007 in our center. One of the
objectives was to speed up the diagnostic and treatment
planning process especially for the loco-regional stages and,
thereby, decrease the waiting times and patients’ anxiety.
In conclusion, our study shows that patients with ad-
vanced NSCLC were treated within a shorter delay than those
with local and regional stages. For the latter, the relationship
between outcome and treatment delay was inconclusive. With
equivalent chemotherapy protocols, advanced patients treated
on a more urgent basis had a worse survival. We hypothesize
that urgent treatment might be a surrogate marker for higher
symptom burden, and this parameter would be useful to
collect in future prospective studies.
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